← Back to Search

Computer Algorithm

Claims-based Algorithm for Amyloidosis

N/A
Recruiting
Led By Edward Miller, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test how well a new algorithm can identify patients with ATTR amyloidosis, a disease where abnormal proteins build up in organs.

Who is the study for?
This trial is for patients within the YNHHS claims dataset who are flagged by a computer algorithm as potentially having ATTR amyloidosis, which includes both hereditary and non-hereditary forms. They must be willing to undergo further clinical evaluation. Pregnant individuals or those opting out of research in the Epic system cannot participate.
What is being tested?
The study is testing the effectiveness of a computer algorithm designed to identify patients at risk of ATTR amyloidosis using medical records data. The goal is to see how well this algorithm predicts actual cases when compared with Yale's list of potential subjects.
What are the potential side effects?
Since this trial involves an evaluation process using a computer algorithm rather than medication, there are no direct side effects from interventions like you would expect with drug trials.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Diagnostic performance of algorithm in identifying patients with ATTR amyloidosis
Secondary study objectives
Proportion of diagnosed patients

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Computer algorithm for ATTRExperimental Treatment1 Intervention
Patients will be evaluated for the identification of ATTR Amyloidosis through a claims-based algorithm

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,920 Previous Clinical Trials
3,031,530 Total Patients Enrolled
1 Trials studying Amyloidosis
650 Patients Enrolled for Amyloidosis
Alnylam Pharmaceuticals IncUNKNOWN
Edward Miller, MDPrincipal InvestigatorYale University

Media Library

ATTR diagnostic algorithm (Computer Algorithm) Clinical Trial Eligibility Overview. Trial Name: NCT04569903 — N/A
Amyloidosis Research Study Groups: Computer algorithm for ATTR
Amyloidosis Clinical Trial 2023: ATTR diagnostic algorithm Highlights & Side Effects. Trial Name: NCT04569903 — N/A
ATTR diagnostic algorithm (Computer Algorithm) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04569903 — N/A
~67 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top